MAGL inhibitors

A method of treating pain in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• is
• X is —O—, —S—, —SO2—, —N(R3)—, or —CH2—;
• Y is —O— or —N(R7)—;
• R1 is —(CR4R5)m—R6, —(CR4R5)p—Y—(CR4R5)q—R6, or —(CR4R5)t—C3-6 cycloalkyl-R6;
• each R2 is independently selected from halogen, —CN, C1-6 alkyl, C1-6 haloalkyl, —C1-6 alkyl(heterocycloalkyl), —OR17, and —C(O)NR18R19;
• R3 is H or C1-6alkyl;
• each R4 and R5 is each independently selected from H, F, and C1-6alkyl;
• or R4 and R5, together with the carbon to which they are attached, form a C3-6 cycloalkyl ring;
• R6 is —CO2R9, —C(O)R10, or —C(O)O—(CR12R13)—OC(O)R11;
• R7 is H, C1-6 alkyl, or —SO2R8;
• R8 is C1-6 alkyl;
• R9 is H or C1-6 alkyl;
• R10 is C1-6 alkyl or —NHSO2R21;
• R11 is C1-6 alkyl or C1-6alkoxy;
• R12 and R13 is each independently H or C1-6 alkyl;
• each R17 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, aminoalkyl, cycloalkyl, —C1-6 alkyl(heterocycloalkyl), —C1-6 alkyl-C(O)(heterocycloalkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
• each R18 and R19 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, aryl, and heteroaryl;
• or R18 and R19, together with the nitrogen to which they are attached, form a heterocycloalkyl ring optionally substituted with one, two, or three R20;
• each R20 is independently selected from halogen, C1-6 alkyl, C1-6 haloalkyl, oxo, —CN, and C3-6 cycloalkyl;
• R21 is C1-6 alkyl;
• m is 1, 2, 3 or 4;
• n is 0, 1, 2, 3, or 4;
• p is 2, 3, or 4;
• q is 1, 2, or 3;
• and
• t is 0, 1, or 2.